North America Dendritic Cell Cancer Vaccines Market

North America Dendritic Cell Cancer Vaccines Market Size (2024 to 2029):

The size of the North America Dendritic Cell Cancer Vaccines Market is forecasted to be hiking at a significant rate during the forecast period.

Dendritic cells (DCs) refer to rare types of leukocytes. They are used in therapeutic cancer vaccines because they are exceptionally effective in presenting antigens to therapeutic T cells in laboratory animals. Cancer is an extremely complex disease, and researchers are still trying to understand the variety of factors responsible for its origin, transmission, metastasis, etc. According to the World Health Organization (WHO) Cancer Vaccine Report, in 2016, 1.8 million new cancer cases were reported in the United States alone. The report also states that the annual incidence of cancer worldwide is expected to rise to 26 million by 2040. Currently, there is a significant need for advanced and effective cancer treatments. North America is expected to become the most dominant region in the global dendritic cell and tumor cell vaccine market, increasing cancer prevalence in the area. According to data from the National Institutes of Health (NIH), in 2019, approximately 624,750 people died from cancer, and the incidence rate was 440.54 per 121,000 men and women per year. The most common cancer types are breast cancer, lung, and bronchial cancer, prostate cancer, colon and rectal cancer, skin melanoma, bladder cancer, and non-lymphoma. Hodgkin's and kidney cancer and renal pelvis. Hence, the higher prevalence of cancer may lead to increased demand for dendritic cell, and tumor cell vaccines and hence is expected to drive the growth of the global dendritic cell and tumor cell vaccines market.

Numerous studies have shown that dendritic cells have the potential ability of combination therapies to limit cancer growth. The assured curable effect of the treatment, which also includes these vaccines, has not been proven; however, they are expected to perform much better than their competitors in the same category. Elevated investment in research and development, coupled with positive results from clinical trials, is anticipated to expand the global dendritic cell cancer vaccine market. 

Other factors driving the expansion of this market include dendritic cells' ability to attack the ability of several cancer antigens, the growing geriatric population, and technological advancements. Computer technology helps oncologists plan and execute hypothetical vaccine replicas to verify their cellular form consequences before moving on to lab tests and using expensive resources.

The withdrawal of dendritic cell and tumor cell vaccines from clinical trials are expected to hamper the global dendritic cell and tumor cell vaccines market.

This research report on the North America Dendritic Cell Cancer Vaccines Market has been segmented and sub-segmented into the following categories:

By Product Type:

• CreaVax
• Sipuleucel-T (Provenge)

By End User:

• Pediatrics
• Adults

By Country:

• The United States
• Canada
• Rest of North America

Regional Analysis:

North America captured the highest share in the global dendritic cell cancer vaccines market in 2022. The US leads the market in this region.

Promising Companies leading the North America Dendritic Cell Cancer Vaccines Market Profiled in the Report are 3M Company, Activarti, Argos Therapeutics, Batavia Bioservices, Bellicum Pharmaceuticals, Creagene, DanDrit Biotech, DCPrime, Sanpower Corporation (Dendreon Corporation). Other players in the market include Elios Therapeutics. ImmunoCellular Therapeutics, Immunicum, Kiromic, Medigene, Merck & co, Northwest Biotherapeutics, Glaxo Smith Kline, ImmunoCellular Therapeutics, Tella Incorporation, and Vaxil BioTherapeutics.